Business Context and Reporting Period
Company: X4 Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: X4 is a biopharmaceutical company focused on rare diseases and immune system dysfunction. In April 2024, the FDA approved its lead product, XOLREMDI (mavorixafor), for the treatment of WHIM syndrome. The company is currently launching XOLREMDI in the U.S. and advancing mavorixafor for chronic neutropenic disorders through Phase 2 and Phase 3 clinical trials.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2024 |
Six Months Ended June 30, 2024 |
Six Months Ended June 30, 2023 |
|---|---|---|---|
| Product Revenue, Net | $563 | $563 | $0 |
| Net Income (Loss) | $90,833 | $39,067 | $(79,732) |
| Net Income (Loss) Per Share (Diluted) | $0.45 | $0.19 | $(0.51) |
| Operating Expenses (Total) | $(70,540) | $(33,251) | $55,109 |
| Research & Development | $20,914 | $40,768 | $37,664 |
| Selling, General & Administrative | $13,278 | $30,713 | $17,445 |
| Cash and Cash Equivalents | $147,218 (as of June 30, 2024) | ||
| Marketable Securities | $21,536 (as of June 30, 2024) | ||
| Long-Term Debt | $75,030 (as of June 30, 2024) | ||
| Net Cash Used in Operating Activities | $(63,874) (Six Months 2024) |
Material Changes vs. Prior Period
- Profitability Shift: The company reported a net income of $90.8 million for the quarter and $39.1 million for the six months ended June 30, 2024, compared to net losses of $55.7 million and $79.7 million, respectively, in the prior year periods. This reversal is primarily driven by a non-recurring gain.
- Gain on Sale of Non-Financial Asset: A one-time gain of $105.0 million was recorded from the sale of a Priority Review Voucher (PRV) awarded by the FDA upon XOLREMDI approval. This transaction significantly impacted operating income and net income.
- Revenue Generation: The company recorded $0.6 million in net product revenue for the first time, following the April 2024 FDA approval of XOLREMDI. There was no product revenue in the comparable 2023 periods.
- Expense Increases: Selling, general, and administrative (SG&A) expenses increased by $13.3 million year-over-year for the six-month period, driven by the build-out of sales and marketing infrastructure for the commercial launch. R&D expenses increased by $3.1 million due to clinical trial costs.
- Debt Expansion: Long-term debt increased from $54.6 million to $75.0 million as the company borrowed an additional $20.0 million term loan under its Hercules Loan Agreement upon achieving an operational milestone.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items: The $105.0 million gain from the PRV sale is non-recurring. Management does not expect to receive or sell a similar voucher in the foreseeable future. Excluding this gain, the company continues to incur operating losses.
- Liquidity and Going Concern: As of June 30, 2024, the company held $168.8 million in cash, cash equivalents, and short-term marketable securities. Management believes this is sufficient to fund operations for at least the next 12 months. However, the company expects to continue incurring losses and will require additional capital beyond this period.
- Debt Covenants: The Hercules Loan Agreement requires the company to maintain a minimum cash balance of $20.0 million through January 31, 2025, and thereafter at least 20% of outstanding borrowings. Failure to meet these covenants could restrict operations.
- Outlook: The company is focused on the U.S. commercial launch of XOLREMDI and advancing the Phase 3 "4WARD" study for chronic neutropenia. Full data from the Phase 2 chronic neutropenia trial is expected in November 2024.
- Risks: Key risks include the unknown market size for WHIM syndrome, dependence on a single product (XOLREMDI) and a single manufacturer for the active pharmaceutical ingredient, and the need for substantial additional funding to sustain operations and development programs.
Investor Verification Checklist
- PRV Sale Impact: Verify the non-recurring nature of the $105 million gain and assess the company's underlying operating cash burn rate excluding this item.
- Commercial Trajectory: Monitor early sales data for XOLREMDI to validate the addressable market size for WHIM syndrome and the effectiveness of the new sales infrastructure.
- Cash Runway: Confirm the company's ability to maintain the $20 million minimum cash covenant under the Hercules Loan Agreement given the high operating cash burn ($63.9 million used in six months).
- Clinical Milestones: Track the enrollment and interim results of the Phase 3 "4WARD" study for chronic neutropenia, which is critical for future revenue expansion beyond WHIM syndrome.
- Manufacturing Dependencies: Review the status of the single-source third-party manufacturers for the active pharmaceutical ingredient and finished drug product to assess supply chain risks.